These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Lin M; Ming A; Zhao M Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149 [TBL] [Abstract][Full Text] [Related]
25. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908 [TBL] [Abstract][Full Text] [Related]
30. Excellent results with calcineurin inhibitor-free initial immunosuppression in old recipients of old kidneys. Bösmüller C; Ollinger R; Mark W; Brandacher G; Schneeberger S; Cakar F; Bonatti H; Margreiter R Transplant Proc; 2005 Mar; 37(2):881-3. PubMed ID: 15848563 [TBL] [Abstract][Full Text] [Related]
31. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653 [TBL] [Abstract][Full Text] [Related]
32. Balancing efficacy and toxicity in kidney-transplant immunosuppression. Leichtman AB N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383 [No Abstract] [Full Text] [Related]
33. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function. González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522 [TBL] [Abstract][Full Text] [Related]
34. A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients. Reinsmoen NL; Kaufman D; Matas A; Sutherland DE; Najarian JS; Bach FH Transplantation; 1990 Nov; 50(5):783-90. PubMed ID: 2146784 [TBL] [Abstract][Full Text] [Related]
35. After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity. van Besouw NM; van de Wetering J; van der Mast BJ; de Kuiper R; Baan CC; Weimar W Clin Transplant; 2008; 22(2):129-35. PubMed ID: 18339130 [TBL] [Abstract][Full Text] [Related]
36. CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Velthuis JH; Mol WM; Weimar W; Baan CC Am J Transplant; 2006 Dec; 6(12):2955-64. PubMed ID: 17294523 [TBL] [Abstract][Full Text] [Related]
37. The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients. Webster AC; Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S75-84. PubMed ID: 17316285 [No Abstract] [Full Text] [Related]
38. Impact of transfusions and acute rejection on posttransplantation donor antigen-specific responses in two study populations. Cooperative Clinical Trial in Transplantation Research Group. Reinsmoen NL; Matas AJ; Donaldson L; Carter S Transplantation; 1999 Mar; 67(5):697-702. PubMed ID: 10096524 [TBL] [Abstract][Full Text] [Related]
39. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity. Jackson A; McSherry C; Butters K; Diko M; Almond PS; Matas AJ; Reinsmoen NL Hum Immunol; 1997 Jul; 55(2):148-53. PubMed ID: 9361966 [TBL] [Abstract][Full Text] [Related]
40. Sequential mixed lymphocyte culture after kidney transplantation: induction of tolerance or sensitization. Creemers P; Du Toit E; Cassidy MJ; Kahn D Nephron; 1997; 75(2):166-70. PubMed ID: 9041536 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]